Equities
Health CareMedical Equipment and Services
  • Price (USD)94.62
  • Today's Change-0.69 / -0.72%
  • Shares traded169.54k
  • 1 Year change-27.64%
  • Beta0.7582
Data delayed at least 15 minutes, as of Aug 17 2022 14:45 BST.
More ▼
Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Profile data is unavailable for this security.

About the company

Medtronic plc is a global healthcare technology company. It develops, manufactures, and markets its medical devices and technologies to hospitals, physicians, clinicians, and patients. Its operating segments include Cardiovascular, Medical Surgical, Neuroscience and Diabetes. Cardiovascular products include pacemakers, insertable cardiac monitors, and cardiac resynchronization therapy devices. Medical Surgical products include patient care from diagnosis to recovery, with a focus on diseases of the gastrointestinal tract, lungs, pelvic region, kidneys, obesity, and preventable complications. Neuroscience products include various spinal implants, bone graft substitutes, biologic products, image-guided surgery and intra-operative imaging systems. Diabetes products include insulin pumps, continuous glucose monitoring (CGM) systems, consumables, and smart insulin pen systems. The Company also provides PROPEL and SINUVA, which is bioabsorbable, steroid-eluting implants for sinus patients.

  • Revenue in USD (TTM)31.69bn
  • Net income in USD5.04bn
  • Incorporated2014
  • Employees95.00k
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
MDT:NYQ since
announced
Transaction
value
Cathworks LtdAnnounced12 Jul 202212 Jul 2022Announced6.37%--
Acutus Medical Inc-Left-Heart Access PortfolioDeal completed27 Apr 202227 Apr 2022Deal completed-11.39%87.00m
Affera IncAnnounced10 Jan 202210 Jan 2022Announced-10.02%--
Triple Jump Israel LtdRumoured17 Oct 202117 Oct 2021Rumoured-25.93%--
Data delayed at least 15 minutes, as of Aug 17 2022 14:45 BST.

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Baxter International Inc14.19bn1.01bn29.69bn60.00k30.013.4113.662.132.002.0027.9917.580.5513.656.32236,550.003.976.034.637.2239.1641.587.2010.021.338.000.652138.319.524.7016.52-23.700.658916.53
DexCom, Inc.2.67bn199.70m33.42bn6.30k189.2815.62104.3113.180.47410.47416.525.750.552.675.12424,349.204.115.564.806.5067.1567.297.478.914.305.490.47350.0027.0833.69-68.66--47.52--
ResMed Inc.3.54bn779.48m34.64bn7.97k45.9010.8737.8410.075.315.3124.1022.420.74592.696.60444,101.9016.4311.9819.6214.0356.2957.6622.0217.491.5633.080.171945.578.1111.70-23.676.1311.495.39
Boston Scientific Corporation12.33bn828.00m58.74bn41.00k72.633.4730.764.860.57630.57638.5812.060.38922.446.86300,707.302.793.263.194.0068.4869.407.168.030.85786.540.34210.0019.927.23956.5223.201.75--
Edwards Lifesciences Corp5.36bn1.46bn62.89bn15.70k44.9410.8340.4712.022.312.318.509.590.66581.598.39341,082.8018.0915.9920.4518.9577.7875.1127.1823.632.60--0.09110.0019.2912.0482.5521.428.69--
Becton Dickinson and Co19.24bn1.52bn72.81bn75.00k48.862.8919.603.835.295.7966.9189.390.35793.468.96256,586.703.002.613.482.9645.1446.638.387.490.90175.360.39172.7918.2910.16161.0215.4511.394.69
Stryker Corporation17.63bn2.08bn81.32bn46.00k40.325.2927.224.705.445.4446.0941.430.50561.736.02383,239.105.966.736.817.9564.8565.5711.7913.161.15--0.460542.3919.218.6024.703.901.3911.20
Intuitive Surgical, Inc.5.96bn1.43bn83.16bn9.79k60.767.0646.9014.243.913.9116.2833.670.45872.947.75608,986.0011.1814.1212.2515.6868.1668.8324.3629.384.74--0.000.0031.0116.1060.7218.2245.67--
Medtronic PLC31.69bn5.04bn123.70bn95.00k25.212.3816.113.953.743.7423.5039.490.34432.235.75333,536.805.505.086.225.7268.5368.4615.9715.451.4917.000.313862.615.211.3043.974.581.767.94
Abbott Laboratories45.55bn8.55bn188.97bn113.00k22.925.2916.194.244.814.8125.6220.840.61773.366.84403,079.7011.605.5914.026.5758.1557.1818.7811.611.5422.500.313463.2224.4715.6157.2446.0810.9511.60
Thermo Fisher Scientific Inc.42.82bn7.44bn227.58bn130.00k31.515.4922.045.4218.8018.80108.20107.950.54114.445.64329,384.609.517.4910.748.5746.6347.2817.5716.381.1322.860.4166.7721.7116.5021.1830.7041.5510.76
Data as of Aug 17 2022. Currency figures normalised to Medtronic PLC's reporting currency: US Dollar USD

Institutional shareholders

31.07%Per cent of shares held by top holders
HolderShares% Held
The Vanguard Group, Inc.as of 30 Jun 2022117.42m8.84%
BlackRock Fund Advisorsas of 30 Jun 202266.57m5.01%
SSgA Funds Management, Inc.as of 31 Mar 202258.50m4.40%
Massachusetts Financial Services Co.as of 30 Jun 202237.46m2.82%
Wellington Management Co. LLPas of 31 Mar 202231.11m2.34%
Geode Capital Management LLCas of 30 Jun 202226.53m2.00%
Capital Research & Management Co. (Global Investors)as of 31 Mar 202222.02m1.66%
T. Rowe Price Associates, Inc. (Investment Management)as of 31 Mar 202219.28m1.45%
Managed Account Advisors LLCas of 30 Jun 202217.75m1.34%
Lazard Asset Management LLCas of 30 Jun 202216.15m1.22%
More ▼
Data from 31 Mar 2022 - 30 Jun 2022Source: FactSet Research Systems Inc.
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.